La diana del fármaco daraxonrasib es el oncogén KRAS. Dos expertas en este tumor analizan el "éxito sin precedentes" de la nueva molécula que se dirige a la vía esencial en cáncer de páncreas Leer
This is the revolutionary drug for pancreatic cancer that is already beginning to benefit the patient
Political Leaning Analysis
Score: 0.00 •
Center / Neutral
Left
Center
Right
Story Timeline
Thu 14:04 - El Mundo (ES)
This is the revolutionary drug for pancreatic cancer that is already beginning to benefit the patient